Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids

Diagnostic Cytopathology

Volumn 32, Issue 3, 2005, Pages 151-155

  Politi, Ekaterini ^a,c   Kandaraki, Christina ^b   Apostolopoulou, Caterina ^b   Kyritsi, Thomais ^b   Koutselini, Helen ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Adenocarcinoma; Effusion; Immunocytochemistry; Mesothelial cells

Indexed keywords

CALRETININ; CANCER ANTIBODY; MONOCLONAL ANTIBODY BER EP4; MONOCLONAL ANTIBODY BG8; MONOCLONAL ANTIBODY HBME 1; MONOCLONAL ANTIBODY MOC 31; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BODY FLUID; CELL PROLIFERATION; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ASCITIC FLUID; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURAL EFFUSION; TUMOR MARKERS, BIOLOGICAL;

EID: 13844269333     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20203     Document Type: Article

References (32)

1. Souhami RL, Beverley PC, Bobrow LG, Ledermann JA. Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst 1991;83:609-612.
2. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathology 1984;8:793-803.
3. Mason MR, Bedrossian CW, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987;3: 215-221.
4. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med 1990;114:845-851.
5. Afify AM, Al-Khafaji BM, Paulino AF, Davila RM. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 2002;10:178-182.
6. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2001;45:18-22.
7. Rogers JH. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987;105:1343-1353.
8. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20: 1037-1046.
9. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216.
10. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997;41:1757-1761.
11. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol 1999;20:125-130.
12. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001;25:158-161.
13. Ruitenbeek T, Gouw AS, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial, and epithelial cells. Arch Pathol Lab Med 1994;118:265-269.
14. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol 1996;40:1212-1216.
15. Jordon D, Jagirdar J, Kaneko M. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-937.
16. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996;179:358-369.
17. Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol 1996;20:293-325.
18. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol 1998;19:131-137.
19. Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000;90:194-200.
20. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 1996;429:213-219.
21. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001;93:68-72.
22. Chen LM, Lazcano O, Katzmann JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998;109:712-721.
23. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990;43:213-219.
24. Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-89.
25. Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies. Acta Cytol 1993;37:439-447.
26. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-120.
27. Kuenen-Boumeester V, van Loenen P, de Bruijn EM, Henzen-Logmans SC. Quality control of immunocytochemical staining of effusions using a standardized method of cell processing. Acta Cytol 1996;40:475-479.
28. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-134.
29. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993;9:516-521.
30. Robinson RJ, Royston D. Comparison of monoclonal antibodies AUA1 and BER EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathology 1993;4:267-271.
31. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-1419.
32. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435: 43-49.